Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
OEM culture media sales fell below plan due to tighter regulations related to cell therapy in China, while infection-related products continued to experience a decline following the previous increase in demand. Meanwhile, contract work related to stem cell projects boosted the cell processing business.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥974 million (YoY -20.1%) |
| Operating profit | ¥-54 million |
| Ordinary income | ¥-36 million |
| Profit attributable to owners of the parent | ¥-41 million |
| Net income per share | (¥8.20) |
| Equity ratio | End of the current fiscal period 66.9 / End of previous period 66.8 |
| Total assets | ¥8,789 million |
| Net assets | ¥5,881 million |
| Cash and cash equivalents at end of period | ¥2,381,664 thousand |
| Full-year earnings forecast | Net Sales ¥4,722 million (YoY -4.4%) / Operating profit ¥137 million (YoY -59.8%) / Ordinary income ¥147 million (YoY -56.8%) / Profit attributable to owners of the parent ¥110 million (YoY -55.9%) |
| Annual Dividend Forecast | ¥10.00 → ¥10.00（0.0%） |
| Segment revenue | Tissue Culture Business ¥472,206 thousand (YoY -24.2%) / Microbiology Business ¥296,378 thousand (YoY -3.0%) / Cell Processing Business ¥205,584 thousand (YoY -29.4%) |
| Segment profit | Tissue Culture Business ¥144,110 thousand (YoY -38.7%) / Microbiology Business ¥-16,797 thousand / Cell Processing Business ¥-56,244 thousand |
| Depreciation and amortization | ¥89,764 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 5,111,600 shares |
| Treasury Shares at Period-End | 0 shares |
| Factors Behind Changes in Business Performance | OEM culture media sales fell below plan due to tighter regulations related to cell therapy in China, while infection-related products continued to experience a decline following the previous increase in demand. Meanwhile, contract work related to stem cell projects boosted the cell processing business. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Regulations related to cell therapy were tightened in China, and sales of OEM culture media fell below plan as clinical activity at some clinics stagnated. In addition, demand for infection-related products continued to decline following the previous increase in demand. Meanwhile, contract work related to stem cell projects performed well in the cell processing business.